Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue , 2015, Pages 45-52

  Jahnsen, Jørgen ^a,b   Detlie, Trond Espen ^a   Vatn, Simen ^a   Ricanek, Petr ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

biosimilar; Crohn's disease; CT P13; efficacy; inflammatory bowel disease; infliximab; Norway; safety; ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; ANTIINFLAMMATORY AGENT; BIOSIMILAR AGENT; CT-P13; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOLITIS; ERYSIPELAS; FATIGUE; FEMALE; HEART PALPITATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NORWAY; OBSERVATIONAL STUDY; PNEUMONIA; PROSPECTIVE STUDY; RASH; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; DRUG ADMINISTRATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84942303588     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1091308     Document Type: Article

References (33)

1. Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13: 5238-44
2. Matricon J, Barnich N, Ardid D. Immunopathogenesis of inflammatory bowel disease. Self Nonself 2010; 1: 299-309
3. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med 2010; 362: 1383-95
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9
5. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849-53
6. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohns disease. N Engl J Med 1999; 340: 1398-405
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76
8. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004; 350: 876-85
9. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. Crohns Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35
10. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11
11. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab). 2013. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002576/WC500151486.pdf. [Last accessed 19 July 2015]
12. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79
13. Norum J, Koldingsnes W, Aanes T, et al. The economic burden of TNFalpha inhibitors and other biologic treatments in Norway. Clinicoecon Outcomes Res 2011; 3: 73-8
14. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006; 23: 451-63
15. Blackstone EA, Fuhr JP Jr. Innovation and competition: will biosimilars succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Health 2012; 9: 24-7
16. Nast A, Mrowietz U, Kragballe K, et al. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis-A multinational cross-sectional study. Arch Dermatol Res 2013; 305: 899-907
17. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73: 198-206
18. World Health Organization. Expert committee on biological standardization. Geneva, 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available from: www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. [Last accessed 19 February 2015]
19. Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs 2014; 6: 1163-77
20. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-12
21. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-20
22. Generics and Biosimilars Initiative. Biosimilars approved in South Korea. 2015. Available from: http://gabionline.net/Biosimilars/General/Biosimilars-Approved-in-South-Korea. [Last accessed 13 March 2015]
23. Generics and Biosimilars Initiative. Biosimilars approved in Japan. 2015. Available from: http://gabionline.net/Biosimilars/General/Biosimilars-Approved-in-Japan. [Last accessed 13 March 2015]
24. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014; 16: 22-6
25. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014; 42: 177-83
26. Health Canada. Summary Basis of Decision (SBD) for Remsima. 2014. Available from: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2014-remsima-160195-eng.php. [Last accessed 28 April 2015]
27. Demonstrate noninferiority in efficacy and to assess safety of CT-P13 in patients with active crohns disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02096861
28. To evaluate the safety and efficacy of remsima™ in patients with Crohns Disease (CD) or Ulcerative Colitis (UC). Available from: https://clinicaltrials.gov/ct2/show/NCT02326155
29. The NOR-SWITCH Study. Available from: https://clinicaltrials.gov/ct2/show/NCT02148640
30. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol 2015. [Epub ahead of print]
31. Farkas K, Rutka M, Bálint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohns disease and ulcerative colitis-experiences from a single center. Expert Opin Biol Ther 2015; 15: 1257-62
32. Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015; 60: 951-6
33. Reinisch W, Louis E, Danese S. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Rev Gastroenterol Hepatol 2015. [Epub ahead of print]